ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1074

Baseline Clinical Features, but Not Shared Epitope or HLA B27, Predict Severe Outcomes for Immune Checkpoint Inhibitor-induced Inflammatory Arthritis

Laura Cappelli1, omer Kamal2, Michelle Jones3, Clifton Bingham4 and Ami Shah5, 1Johns Hopkins School of Medicine, Baltimore, MD, 2St. Agnes Hospital, Baltimore, MD, 3Johns Hopkins University School of Medicine, Baltimore, MD, 4Johns Hopkins University, Baltimore, MD, 5Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD

Meeting: ACR Convergence 2023

Keywords: autoimmune diseases, Oncology, risk factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1052–1081) Immunological Complications of Medical Therapy Poster

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Immune checkpoint inhibitors (ICI) can cause inflammatory arthritis (IA) of varying severity. Many patients with ICI-IA require immunosuppression beyond corticosteroids, but there is no way to identify these patients at initial presentation. We determined baseline risk factors for requiring immunosuppression and having persistent arthritis in ICI-IA.

Methods: participants were adults with rheumatologist diagnosed ICI-IA. The primary outcome was requirement of conventional synthetic (cs) or biologic (b) DMARDs; other outcomes were persistence of IA >6 months after ICI cessation and requirement of corticosteroids. Logistic regression models evaluated associations between clinical/genetic features and primary and secondary outcomes, with adjustment for potential confounders, as appropriate. Finally, we evaluated the relationship between maximum prior dose of steroids and primary and secondary outcomes with simple logistic regression.

Results: 126 patients with ICI-IA were included; 53 patients (42%) required a csDMARD/bDMARD (demographic and clinical features by DMARD group in Table 1).In univariate logistic regressions, higher CDAI, tenosynovitis, longer symptom duration before first rheumatology visit, and longer ICI duration were significantly associated with a higher likelihood of requiring DMARDs; there was a trend toward those treated with prior chemotherapy being less likely to need DMARDs (Table 2). After adjustment, tenosynovitis, longer symptom duration, and higher CDAI remained associated with requiring DMARDs, while those with prior chemotherapy were significantly less likely to require DMARDs (Table 2). Combination anti-CTLA-4/PD-1 therapy and steroid use at baseline were associated with a higher risk of persistent IA (Table 2). For 98 patients with HLA typing data, there was no significant association with HLA DRB1 shared epitope alleles or HLA B27 and primary or secondary outcomes. For 62 patients reporting systemic steroid use after starting ICI therapy, but prior to their baseline visit with rheumatology, there were no differences between those treated with low dose (prednisone or equivalent ≤ 10 mg/daily), moderate dose (10 mg< prednisone daily ≤60 mg), or high dose (prednisone daily > 60 mg) corticosteroids in either requiring a csDMARD/biologic or having persistent ICI-IA.

Conclusion: Higher levels of disease activity, tenosynovitis, and longer symptom duration prior to baseline were associated with requiring DMARDs for ICI-IA, while those treated previously with chemotherapy were less likely to require DMARDs. Known genetic risk factors for traditional forms of IA were not predictive. The presence of risk factors for severe disease at baseline may indicate a role for higher initial steroid dose, earlier rheumatology referral, and adoption of immunosuppression beyond steroids to improve outcomes.

Supporting image 1

Table 1: Demographic features, cancer history, shared epitope/HLA B27 status, and selected arthritis clinical variables by DMARD requirement

Supporting image 2

Table 2: Unadjusted and adjusted Odds Ratios for association with primary and secondary outcomes


Disclosures: L. Cappelli: Bristol-Myers Squibb(BMS), 5, Mallincrkrodt, 2; o. Kamal: None; M. Jones: None; C. Bingham: AbbVie/Abbott, 2, Bristol-Myers Squibb(BMS), 5, Eli Lilly, 2, Janssen, 2, Pfizer, 2, Sanofi, 2; A. Shah: Arena Pharmaceuticals, 5, Eicos Sciences, 5, Kadmon Corporation, 5, Medpace LLC, 5.

To cite this abstract in AMA style:

Cappelli L, Kamal o, Jones M, Bingham C, Shah A. Baseline Clinical Features, but Not Shared Epitope or HLA B27, Predict Severe Outcomes for Immune Checkpoint Inhibitor-induced Inflammatory Arthritis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/baseline-clinical-features-but-not-shared-epitope-or-hla-b27-predict-severe-outcomes-for-immune-checkpoint-inhibitor-induced-inflammatory-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/baseline-clinical-features-but-not-shared-epitope-or-hla-b27-predict-severe-outcomes-for-immune-checkpoint-inhibitor-induced-inflammatory-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology